Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/68888
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Long-term benefit of the TAXUS Liberté stent in small vessels and long lesions - TAXUS ATLAS program - |
Other Titles: | Long-term benefit of the TAXUS liberte stent in small vessels and long lesions - TAXUS ATLAS program - |
Author: | Ormiston, J. Turco, M. Hall, J. Cannon, L. Yakubov, S. Lucca, M. Stone, G. O'Shaughnessy, C. Kozina, J. Gilchrist, I. Bertolet, B. Worthley, S. Underwood, P. Dawkins, K. |
Citation: | Circulation Journal, 2011; 75(5):1120-1129 |
Publisher: | Blackwell Science Asia |
Issue Date: | 2011 |
ISSN: | 1346-9843 1347-4820 |
Statement of Responsibility: | John A. Ormiston; Mark A. Turco; Jack J. Hall; Louis A. Cannon; Steven J. Yakubov; Michael J. Lucca; Gregg W. Stone; Charles D. O'Shaughnessy; Joseph A. Kozina; Ian C. Gilchrist; Barry D. Bertolet; Stephen G. Worthley; Paul L. Underwood; Keith D. Dawkins |
Abstract: | Background: The long-term impact of treating de novo coronary lesions in native vessels and challenging small vessel and long lesion subsets with TAXUS Liberté stents is unknown. This report examines the 3-year efficacy and safety from the TAXUS ATLAS program. Methods and Results: TAXUS ATLAS WH, Small Vessel, and Long Lesion are non-randomized studies comparing TAXUS Liberté (n=871), TAXUS Liberté 2.25mm (n=261), and TAXUS Liberté 38mm (n=150) stents, respectively, to case-matched TAXUS Express historical controls. TAXUS Liberté demonstrated comparable 3-year rates of major adverse cardiac events (19.0% vs. 20.2%, P=0.51) in de novo lesions, reduced target lesion revascularization (TLR, 10.0% vs. 22.1%, P=0.008) in small vessels, and reduced myocardial infarction (MI, 2.9% vs. 10.4%; P=0.01) and stent thrombosis (ST, 0.0% vs. 3.9%, P=0.03) in long lesions vs. TAXUS Express. After propensity score adjustment, no statistically significant effect of TAXUS Liberté on TLR (9.7% vs. 16.9%, P=0.12) in small vessels or MI (2.9% vs. 7.9%, P=0.05) in long lesions was noted, although reduced ST (0.0% vs. 2.7%, P=0.02) remained in long lesions. Multivariate analyses demonstrated that TAXUS Liberté treatment significantly reduced TLR by 66% in small vessels, and MI by 75% in long lesions, vs. TAXUS Express. Conclusions: TAXUS Liberté suggests durable 3-year effectiveness in reducing restenosis and improved clinical outcomes in small vessels and long lesions compared with TAXUS Express. |
Keywords: | Paclitaxel-eluting stent Stent designs Stent thrombosis |
Rights: | All rights are reserved to the Japanese Circulation Society. |
DOI: | 10.1253/circj.CJ-10-0848 |
Published version: | http://dx.doi.org/10.1253/circj.cj-10-0848 |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.